$MDXG
MIMEDX GROUP, INC. Stock $mdxg

$mdxg Overview Financials Valuation SEC Filings Company Website

2014 Form 10-K Financial Statement

#000137633915000040 Filed on March 13, 2015

Income Statement

Concept	2014	2013 Q4	2013
Revenue	$118.2M	$17.99M	$59.18M
YoY Change	99.77%	71.22%	118.76%
Cost Of Revenue	$12.67M	$3.110M	$9.328M
YoY Change	35.77%	84.02%	79.8%
Gross Profit	$105.6M	$14.88M	$49.85M
YoY Change	111.74%	68.74%	128.0%
Gross Profit Margin	89.29%	82.71%	84.24%
Selling, General & Admin	$90.48M	$14.28M	$46.23M
YoY Change	95.73%	75.21%	135.96%
% of Gross Profit	85.72%	95.95%	92.73%
Research & Development	$7.050M	$1.380M	$4.843M
YoY Change	45.57%	21.05%	67.87%
% of Gross Profit	6.68%	9.27%	9.71%
Depreciation & Amortization	$1.197M	$480.0K	$637.0K
YoY Change	87.91%	26.32%	36.99%
% of Gross Profit	1.13%	3.23%	1.28%
Operating Expenses	$97.53M	$15.93M	$51.07M
YoY Change	90.97%	62.72%	127.22%
Operating Profit	$7.100M	-$1.047M	-$2.639M
YoY Change	-369.04%	7.94%	-50.73%
Interest Expense	$48.00K	-$10.00K	$45.00K
YoY Change	6.67%	-98.41%	-92.41%
% of Operating Profit	0.68%
Other Income/Expense, Net
YoY Change
Pretax Income	$7.052M	-$1.420M	-$4.012M
YoY Change	-275.77%	-11.8%	-47.64%
Income Tax	$832.0K	$0.00	$100.0K
% Of Pretax Income	11.8%
Net Earnings	$6.220M	-$1.427M	-$4.112M
YoY Change	-251.26%	-11.09%	-46.34%
Net Earnings / Revenue	5.26%	-7.93%	-6.95%
Basic Earnings Per Share	$0.06	-$0.01	-$0.04
Diluted Earnings Per Share	$0.05	-$0.01	-$0.04
COMMON SHARES
Basic Shares Outstanding	105.8M shares	97.85M shares	96.29M shares
Diluted Shares Outstanding	113.3M shares		96.29M shares

Balance Sheet

Concept	2014	2013 Q4	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$52.30M	$44.10M	$44.10M
YoY Change	18.59%	548.53%	548.53%
Cash & Equivalents	$46.60M	$44.08M	$44.10M
Short-Term Investments	$5.800M
Other Short-Term Assets	$1.500M	$1.300M	$1.300M
YoY Change	15.38%	85.71%	85.71%
Inventory	$5.100M	$3.881M	$3.900M
Prepaid Expenses
Receivables	$26.70M	$16.09M	$16.10M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$85.70M	$65.39M	$65.40M
YoY Change	31.04%	261.49%	261.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.400M	$4.086M	$4.100M
YoY Change	31.71%	281.29%	272.73%
Goodwill		$4.040M
YoY Change		-0.01%
Intangibles		$11.18M
YoY Change		-6.15%
Long-Term Investments	$3.300M
YoY Change
Other Assets		$0.00
YoY Change		-100.0%
Total Long-Term Assets	$23.60M	$19.31M	$19.30M
YoY Change	22.28%	12.94%	12.87%
TOTAL ASSETS
Total Short-Term Assets	$85.70M	$65.39M	$65.40M
Total Long-Term Assets	$23.60M	$19.31M	$19.30M
Total Assets	$109.3M	$84.69M	$84.70M
YoY Change	29.04%	140.73%	140.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.700M	$2.491M	$2.500M
YoY Change	48.0%	98.97%	92.31%
Accrued Expenses	$14.00M	$1.406M	$7.000M
YoY Change	100.0%	41.92%	89.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.40M	$9.608M	$9.600M
YoY Change	91.67%	91.5%	92.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$1.500M	$1.518M	$1.500M
YoY Change	0.0%	329.62%	-75.41%
Total Long-Term Liabilities	$1.500M	$1.518M	$1.500M
YoY Change	0.0%	-65.23%	-85.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.40M	$9.608M	$9.600M
Total Long-Term Liabilities	$1.500M	$1.518M	$1.500M
Total Liabilities	$19.90M	$11.13M	$11.10M
YoY Change	79.28%	-26.68%	-26.97%
SHAREHOLDERS EQUITY
Retained Earnings		-$73.80M
YoY Change		5.9%
Common Stock		$104.0K
YoY Change		17.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$25.00K
YoY Change		0.0%
Treasury Stock Shares		50.00K shares
Shareholders Equity	$89.30M	$73.57M	$73.60M
YoY Change
Total Liabilities & Shareholders Equity	$109.3M	$84.69M	$84.70M
YoY Change	29.04%	140.73%	140.63%

Cashflow Statement

Concept	2014	2013 Q4	2013
OPERATING ACTIVITIES
Net Income	$6.220M	-$1.427M	-$4.112M
YoY Change	-251.26%	-11.09%	-46.34%
Depreciation, Depletion And Amortization	$1.197M	$480.0K	$637.0K
YoY Change	87.91%	26.32%	36.99%
Cash From Operating Activities	$16.80M	$830.0K	-$284.0K
YoY Change	-6016.2%	-195.4%	-91.48%
INVESTING ACTIVITIES
Capital Expenditures	-$3.150M	-$500.0K	-$3.030M
YoY Change	3.96%	108.33%	373.44%
Acquisitions	$0.00		$0.00
YoY Change
Other Investing Activities	-$9.000M	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$12.15M	-$500.0K	-$3.026M
YoY Change	301.59%	108.33%	375.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$2.146M	37.66M	$40.63M
YoY Change	-105.28%	15591.67%	514.74%
NET CHANGE
Cash From Operating Activities	$16.80M	830.0K	-$284.0K
Cash From Investing Activities	-$12.15M	-500.0K	-$3.026M
Cash From Financing Activities	-$2.146M	37.66M	$40.63M
Net Change In Cash	$2.504M	37.99M	$37.32M
YoY Change	-93.29%	-4466.67%	1313.25%
FREE CASH FLOW
Cash From Operating Activities	$16.80M	$830.0K	-$284.0K
Capital Expenditures	-$3.150M	-$500.0K	-$3.030M
Free Cash Flow	$19.95M	$1.330M	$2.746M
YoY Change	626.58%	-311.11%	-202.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001376339
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	106594879	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	657000000	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	MIMEDX GROUP, INC.
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	mdxg	Adjustments To Additional Paid In Capital Related Party AdjustmentsToAdditionalPaidInCapitalRelatedParty	514000	USD
CY2012	mdxg	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	216000	USD
CY2013	mdxg	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	0	USD
CY2014	mdxg	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	0	USD
CY2014Q4	mdxg	Current Assetsand Liabilities Net CurrentAssetsandLiabilitiesNet	67300000	USD
CY2013Q4	mdxg	Deferred Tax Assets Federaland State Basis Difference DeferredTaxAssetsFederalandStateBasisDifference	0	USD
CY2014Q4	mdxg	Deferred Tax Assets Federaland State Basis Difference DeferredTaxAssetsFederalandStateBasisDifference	114000	USD
CY2014Q4	mdxg	Deferred Tax Assetsthat Would Impact Equity Sharebased Compensation DeferredTaxAssetsthatWouldImpactEquitySharebasedCompensation	5676000	USD
CY2014	mdxg	Defined Benefit Plan Maximum Pre Tax Contributions By Plan Participants DefinedBenefitPlanMaximumPreTaxContributionsByPlanParticipants	5500	USD
CY2014	mdxg	Defined Contribution Plan Maximum Percentage Of Eligible Wages Deferred By Participants DefinedContributionPlanMaximumPercentageOfEligibleWagesDeferredByParticipants	1
CY2012	mdxg	Fair Value Adjustment Of Earn Out Liability FairValueAdjustmentOfEarn-OutLiability	1567000	USD
CY2013	mdxg	Fair Value Adjustment Of Earn Out Liability FairValueAdjustmentOfEarn-OutLiability	0	USD
CY2014	mdxg	Fair Value Adjustment Of Earn Out Liability FairValueAdjustmentOfEarn-OutLiability	0	USD
CY2012	mdxg	Fair Value Adjustmentof Earn Out Liability FairValueAdjustmentofEarnOutLiability	1567000	USD
CY2013	mdxg	Fair Value Adjustmentof Earn Out Liability FairValueAdjustmentofEarnOutLiability	0	USD
CY2014	mdxg	Fair Value Adjustmentof Earn Out Liability FairValueAdjustmentofEarnOutLiability	0	USD
CY2012	mdxg	Impairmentof Intangible Assets ImpairmentofIntangibleAssets	1798000	USD
CY2013	mdxg	Impairmentof Intangible Assets ImpairmentofIntangibleAssets	368000	USD
CY2014	mdxg	Impairmentof Intangible Assets ImpairmentofIntangibleAssets	0	USD
CY2013Q4	mdxg	Intangible Assets Accumulated Amortization IntangibleAssetsAccumulatedAmortization	3003000	USD
CY2014Q4	mdxg	Intangible Assets Accumulated Amortization IntangibleAssetsAccumulatedAmortization	3931000	USD
CY2014	mdxg	Maximum Eligible Wages Deferred By Participants Per Year MaximumEligibleWagesDeferredByParticipantsPerYear	17500	USD
CY2014	mdxg	Minimum Age For Additional Contribution Beyond Normal Plan MinimumAgeForAdditionalContributionBeyondNormalPlan	P50Y
CY2014	mdxg	Minimum Age Require To Qualify For Pension Plan MinimumAgeRequireToQualifyForPensionPlan	P21Y
CY2014	mdxg	Minimum Service Period Require To Qualify For Pension Plan MinimumServicePeriodRequireToQualifyForPensionPlan	P3M
CY2012	mdxg	Noncash Stock Issued Acquisition NoncashStockIssuedAcquisition	893000	USD
CY2013	mdxg	Noncash Stock Issued Acquisition NoncashStockIssuedAcquisition	0	USD
CY2014	mdxg	Noncash Stock Issued Acquisition NoncashStockIssuedAcquisition	0	USD
CY2014Q4	mdxg	Number Of Major Customers NumberOfMajorCustomers	1	distributor
CY2014	mdxg	Number Of Share Based Compensation Plans NumberOfShareBasedCompensationPlans	3	plan
CY2014	mdxg	Numberof Patients NumberofPatients	150	patient
CY2014Q4	mdxg	Outstanding Assumed Options OutstandingAssumedOptions	195000	shares
CY2012	mdxg	Paymentsfor Application Costs Patent PaymentsforApplicationCostsPatent	0	USD
CY2013	mdxg	Paymentsfor Application Costs Patent PaymentsforApplicationCostsPatent	689000	USD
CY2014	mdxg	Paymentsfor Application Costs Patent PaymentsforApplicationCostsPatent	594000	USD
CY2012	mdxg	Repurchase Of Warrants RepurchaseOfWarrants	1000	USD
CY2013	mdxg	Stock Issued During Period Shares Accrued Director Fees StockIssuedDuringPeriodSharesAccruedDirectorFees	167086	shares
CY2013	mdxg	Stock Issued During Period Shares Cashless Exercise StockIssuedDuringPeriodSharesCashlessExercise	216085	shares
CY2013	mdxg	Stock Issued During Period Shares For Earn Out Liability StockIssuedDuringPeriodSharesForEarnOutLiability	2632576	shares
CY2014	mdxg	Stock Issued During Period Shares For Earn Out Liability StockIssuedDuringPeriodSharesForEarnOutLiability	1174915	shares
CY2013	mdxg	Stock Issued During Period Shares Issued For Payment Of Line Of Credit With Related Party StockIssuedDuringPeriodSharesIssuedForPaymentOfLineOfCreditWithRelatedParty	1403630	shares
CY2012	mdxg	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	6001000	USD
CY2013	mdxg	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	2108000	USD
CY2014	mdxg	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1113000	USD
CY2012	mdxg	Stock Issued During Period Value For Accrued Director Fees StockIssuedDuringPeriodValueForAccruedDirectorFees	184000	USD
CY2013	mdxg	Stock Issued During Period Value For Accrued Director Fees StockIssuedDuringPeriodValueForAccruedDirectorFees	0	USD
CY2014	mdxg	Stock Issued During Period Value For Accrued Director Fees StockIssuedDuringPeriodValueForAccruedDirectorFees	0	USD
CY2012	mdxg	Stock Issued During Period Value For Earn Out Liability StockIssuedDuringPeriodValueForEarnOutLiability	3186000	USD
CY2013	mdxg	Stock Issued During Period Value For Earn Out Liability StockIssuedDuringPeriodValueForEarnOutLiability	5792000	USD
CY2014	mdxg	Stock Issued During Period Value For Earn Out Liability StockIssuedDuringPeriodValueForEarnOutLiability	0	USD
CY2012	mdxg	Stock Issued During Period Value Issued For Payment Of Line Of Credit With Related Party StockIssuedDuringPeriodValueIssuedForPaymentOfLineOfCreditWithRelatedParty	1403000	USD
CY2013	mdxg	Stock Issued During Period Value Issued For Payment Of Line Of Credit With Related Party StockIssuedDuringPeriodValueIssuedForPaymentOfLineOfCreditWithRelatedParty	0	USD
CY2014	mdxg	Stock Issued During Period Value Issued For Payment Of Line Of Credit With Related Party StockIssuedDuringPeriodValueIssuedForPaymentOfLineOfCreditWithRelatedParty	0	USD
CY2014	mdxg	Warrants Term WarrantsTerm	P5Y
CY2013Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	2491000	USD
CY2014Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	3661000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16093000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26672000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1406000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2504000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	147284000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2302000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3499000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	162433000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2539000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6010000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11453000	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	20000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	27000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1714000	USD
CY2013	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1328000	USD
CY2014	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1380000	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1054000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	928000	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7502496	shares
CY2013Q4	us-gaap	Assets Assets	84694000	USD
CY2014Q4	us-gaap	Assets Assets	109259000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	65389000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	85677000	USD
CY2012	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	85000	USD
CY2013	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	355000	USD
CY2014	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4113000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6754000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44078000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46582000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2641000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	37324000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2504000	USD
CY2010Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2014Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	44600000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	104425614	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	108776247	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	104375614	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107789611	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	108000	USD
CY2014Q4	us-gaap	Contractual Obligation ContractualObligation	7107000	USD
CY2014Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	120000	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	1434000	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	2094000	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	1924000	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	1535000	USD
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5188000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	9328000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12665000	USD
CY2012	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	514000	USD
CY2013	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2014	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	1000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	1000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1163000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	619000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	20244000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	16158000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14663000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6382000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	-507000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	-770000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1369000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2086000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2151000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4163000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1404000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3563000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20244000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16158000	USD
CY2014	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2012	us-gaap	Depreciation Depreciation	465000	USD
CY2013	us-gaap	Depreciation Depreciation	637000	USD
CY2014	us-gaap	Depreciation Depreciation	1197000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0248
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1180
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.1273
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0592
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0.0000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0.0555
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11523000	USD
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	15084000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0000
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0559
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.2173
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.4673
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.5873
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0248
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0958
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5588000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	5479000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	929000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	830000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	830000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	840000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	929000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9837000	USD
CY2012	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-37000	USD
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013Q4	us-gaap	Goodwill Goodwill	4040000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	4040000	USD
CY2012Q3	us-gaap	Gross Profit GrossProfit	6529000	USD
CY2012Q4	us-gaap	Gross Profit GrossProfit	8820000	USD
CY2012	us-gaap	Gross Profit GrossProfit	21865000	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	9651000	USD
CY2013Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	30000	USD
CY2012Q1	us-gaap	Gross Profit GrossProfit	2747000	USD
CY2012Q2	us-gaap	Gross Profit GrossProfit	3769000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	11316000	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	14002000	USD
CY2013Q4	us-gaap	Gross Profit GrossProfit	14883000	USD
CY2013	us-gaap	Gross Profit GrossProfit	49853000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	16582000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	22833000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	30170000	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	35973000	USD
CY2014	us-gaap	Gross Profit GrossProfit	105558000	USD
CY2012	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1800000	USD
CY2013	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	368000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7663000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4012000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	7052000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	832000	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	61000	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	384000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-81000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1209000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1287000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5762000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8439000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10579000	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	606000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	353000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1098000	USD
CY2012	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	2355000	USD
CY2013	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	2836000	USD
CY2014	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	5935000	USD
CY2012	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	388000	USD
CY2013	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-42000	USD
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2310000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	858000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1252000	USD
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-97000	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-70000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	41000	USD
CY2013	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-28000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	718000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	466000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	707000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	203000	USD
CY2013Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	14182000	USD
CY2014Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	14776000	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	26500000	shares
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10845000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11179000	USD
CY2012	us-gaap	Interest Expense InterestExpense	593000	USD
CY2013	us-gaap	Interest Expense InterestExpense	45000	USD
CY2014	us-gaap	Interest Expense InterestExpense	48000	USD
CY2012	us-gaap	Interest Paid InterestPaid	13000	USD
CY2013	us-gaap	Interest Paid InterestPaid	36000	USD
CY2014	us-gaap	Interest Paid InterestPaid	48000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1049000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1986000	USD
CY2013Q4	us-gaap	Inventory Gross InventoryGross	4203000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	5660000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	3881000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	5133000	USD
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	202000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	255000	USD
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	322000	USD
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	527000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2952000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3419000	USD
CY2013Q4	us-gaap	Investments Investments	0	USD
CY2014Q4	us-gaap	Investments Investments	3250000	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	485000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1000000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1130000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	11126000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	19930000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	84694000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109259000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9608000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18404000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6610000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40634000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2146000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-637000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3026000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12152000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3332000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-284000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	16802000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-1094000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-744000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-4219000	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-1605000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-7663000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-1620000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-757000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	11453000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-307000	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	997000	USD
CY2014	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0	USD
CY2012	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2013	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	102000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-1427000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4112000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-922000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-390000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	3700000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	3832000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	6220000	USD
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Business_Segment
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-5356000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-2639000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	7100000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	123000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	716000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1518000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1526000	USD
CY2012	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1000	USD
CY2013	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2012	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2012	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	16000	USD
CY2013	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	57000	USD
CY2014	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	117000	USD
CY2012	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	637000	USD
CY2013	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	2337000	USD
CY2014	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	2558000	USD
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9000000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1337000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1540000	USD
CY2013	us-gaap	Proceeds From Grantors ProceedsFromGrantors	250000	USD
CY2014Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	39573000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2885000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	118223000	USD
CY2012	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2013	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	36602000	USD
CY2014	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2012	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	0	USD
CY2013	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	0	USD
CY2014	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	-5612000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1053000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1981000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2470000	USD
CY2012	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6001000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2108000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1113000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6388000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8946000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4086000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5447000	USD
CY2012	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	202000	USD
CY2013	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	81000	USD
CY2014	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	51000	USD
CY2012	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	427000	USD
CY2013	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2014	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4843000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7050000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73795000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67575000	USD
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3706000	USD
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4884000	USD
CY2012Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	7954000	USD
CY2012Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10509000	USD
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	27053000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11556000	USD
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13515000	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	16116000	USD
CY2013Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	17994000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	59181000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	19559000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	25573000	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33518000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19591000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46227000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	90480000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	2539000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	6010000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8864000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0177
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10566000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	84332	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	296680	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3132969	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.08
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.18
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	133360210	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15375960	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16474227	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.46
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.43
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	131953654	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	9280650	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0188
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0196
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0062
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0085
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0164
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	4000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	16198892	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.97
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	719000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.38
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	88716569	USD
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.49
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.81
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.09
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.20
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	9280650	shares
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	16474227	shares
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	8568228	shares
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	7193577	shares
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	296680	shares
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	4.09
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.94
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.08
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y3M18D
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1851000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3351000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6615000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.58
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.97
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	4210940	shares
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3.43
CY2014	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	5750000	USD
CY2012	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	893267	shares
CY2013	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	893267	shares
CY2014	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	893267	shares
CY2014	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	5272004	shares
CY2014	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	15958	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1653690	shares
CY2012	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	893000	USD
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5272000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2012	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	117000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	36510000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2539000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6010000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11453000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1053000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1981000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2470000	USD
	us-gaap	Stock Repurchase Program Authorized Amount StockRepurchaseProgramAuthorizedAmount	10000000	USD
CY2014	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	4400000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	11898000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	20007000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	73568000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	89329000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	50000	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	986636	shares
CY2014	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	940000	shares
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	25000	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	5637000	USD
CY2014	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	5612000	USD
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2013	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2014	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	7502496	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81646295	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96285504	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113295504	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81646295	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96285504	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105793008	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Concentrations and Credit Risk</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company places its cash and cash equivalents on deposit with financial institutions in the United States.  In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;"> for substantially all depository accounts. As of December 31, 2014, the Company had cash and cash equivalents of approximately </font><font style="font-family:inherit;font-size:10pt;">$44,600,000</font><font style="font-family:inherit;font-size:10pt;"> in excess of the insured amounts.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s principal market concentration of risk is related to its limited distribution channels.  The Company's revenues include the distribution efforts of several independent companies as well as the Company's internal sales force. Significant revenues are derived from its relationship with </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> of its distributors, AvKare, Inc. which sells our products to the Federal government.</font></div></div>
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of Business</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiMedx Group, Inc. (“MiMedx,” "the Company,” “we,” or “us”) operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.  The Company's biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, and device technology CollaFix</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™ </sup></font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">which the Company has yet to commercialize.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is focused primarily on the United States but will pursue other individual markets based upon the specific opportunity.  The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.</font></div></div>
CY2014	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grant Income</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company received a Regional Economic Business Assistance ("REBA") grant in the amount of </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;"> from the State of Georgia to help the Company defray certain expenses and capital expenditures related to the Company's expansion of manufacturing activities in the State.  In order to retain the grant monies the Company was required to add a certain number of full time positions and spend a certain amount on capital and operations expenditures by December 31, 2014. As of December 31, 2013, the Company had satisfied the grant requirements. Accordingly, the Company recorded the </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;"> as a reduction of Selling, General and Administrative expenses in the accompanying 2013 Consolidated Statements of Operations. </font></div></div>
CY2014	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products primarily through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets.  The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance.  In cases where the Company utilizes distributors or ships products directly to the end user, it recognizes revenue according to the shipping terms of the agreement provided all revenue recognition criteria have been met.  A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives.  For these products, revenue is recognized at the time the product has been used or implanted.  The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.</font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period.  Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001376339-15-000040-index-headers.html	Edgar Link	pending
0001376339-15-000040-index.html	Edgar Link	pending
0001376339-15-000040.txt	Edgar Link	pending
0001376339-15-000040-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mdxg-20141231.xml	Edgar Link	completed
mdxg-20141231.xsd	Edgar Link	pending
mdxg-20141231x10k.htm	Edgar Link	pending
mdxg-20141231x10xkex211.htm	Edgar Link	pending
mdxg-20141231x10xkex231con.htm	Edgar Link	pending
mdxg-20141231x10xkex311.htm	Edgar Link	pending
mdxg-20141231x10xkex312.htm	Edgar Link	pending
mdxg-20141231x10xkex321.htm	Edgar Link	pending
mdxg-20141231x10xkex322.htm	Edgar Link	pending
mdxg-20141231_cal.xml	Edgar Link	unprocessable
mdxg-20141231_def.xml	Edgar Link	unprocessable
mdxg-20141231_lab.xml	Edgar Link	unprocessable
mdxg-20141231_pre.xml	Edgar Link	unprocessable
mdxg-20141_chartx41044.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDXG
MIMEDX GROUP, INC. Stock $mdxg

2014 Form 10-K Financial Statement

#000137633915000040 Filed on March 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDXG MIMEDX GROUP, INC. Stock $mdxg

2014 Form 10-K Financial Statement

#000137633915000040 Filed on March 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDXG
MIMEDX GROUP, INC. Stock $mdxg